eFoodSafety's Cinnergen(TM) Gains Momentum as an All-Natural Alternative to Prescription Diabetic Medications.

FDA Will Now Require "Black-Box" Warnings on Several Prescription Diabetes Drugs

SCOTTSDALE, Ariz. -- eFoodSafety.com, Inc. (OTCBB: EFSF) today reported that the Food and Drug Administration (FDA) is now requiring "black-box" warnings on the prescription diabetic drugs, Avandia and Actos. These warnings, the most severe that prescription drugs can bear, stress that these medicines may cause or worsen heart failure and that patients being administered these drugs should be closely monitored.

This heightened awareness and concern relating to possible adverse effects of these prescription diabetes drugs have caused consumers to focus their attention on all natural, clinically proven alternatives, such as the Company's Cinnergen[TM]. It's anticipated that Cinnergen[TM] should continue to gain recognition as a viable alternative to prescription medication for diabetes as the side effects of prescription drugs become more prevalent and defined.

The prescriptive drug hazards, coupled with the overwhelmingly positive product testimonials the Company has received on Cinnergen[TM], led the Company to invest significant capital into its e-commerce site, which is currently undergoing beta testing, with excellent initial results.

Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "This event further solidifies our belief that the best solution to the diabetes epidemic may be a natural one as prescription drugs can heighten and agitate other health risks. With our Cinnergen[TM], we have successfully found a clinically proven alternative to promoting healthy glucose metabolism without the adverse side effects of prescription drugs. It remains our goal to continue to develop and bring to market additional non-toxic treatments for other critical medical conditions."

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn[TM]-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn[TM] line. The Company is also owner of Cinnergen[TM], a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol[TM], a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect[TM] anti-acne skin care system.

Please visit the Company's website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.